Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 3/20 | 0.31 |
| ▸ | IKBKB | O14920 | 2/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918796 | 0.71 | DGAT1 (0.38) | BRD4MEN1ALDH1A1MAPTMAPK1 | |
| SCHEMBL19490573 | 0.68 | CDC7 (0.41) | HCAR2BRD4MEN1ALDH1A1MAPT | |
| SCHEMBL9918749 | 0.65 | CYP1A2 (0.49) | ALDH1A1MAPTMAPK1 | |
| SCHEMBL24490640 | 0.65 | CDC7 (0.48) | HCAR2BRD4MEN1ALDH1A1MAPT | |
| SCHEMBL4351487 | 0.64 | BRD4 (0.68) | BRD4CDC7IKBKB | |
| SCHEMBL4343610 | 0.63 | CDC7 (0.45) | BRD4CDC7 | |
| SCHEMBL7124498 | 0.63 | BRD4 (0.38) | ERN1BRD4CDC7MAP2K1 | |
| SCHEMBL4348090 | 0.62 | BRD4 (0.41) | BRD4MAPK1CDC7 | |
| SCHEMBL2196043 | 0.62 | CDC7 (0.61) | BRD4MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4346525 | 0.62 | CDC7 (0.61) | BRD4CDC7MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ERN1 616/4885HCAR2 1777/4885CYP2A6 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.